NasdaqGS - Nasdaq Real Time Price USD

Bio-Techne Corporation (TECH)

64.06 +1.40 (+2.23%)
At close: April 26 at 4:00 PM EDT
64.06 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Key Events
Loading Chart for TECH
DELL
  • Previous Close 62.66
  • Open 62.72
  • Bid 64.04 x 100
  • Ask 64.19 x 400
  • Day's Range 62.49 - 64.36
  • 52 Week Range 51.79 - 89.91
  • Volume 946,213
  • Avg. Volume 1,093,892
  • Market Cap (intraday) 10.07B
  • Beta (5Y Monthly) 1.22
  • PE Ratio (TTM) 46.09
  • EPS (TTM) 1.39
  • Earnings Date May 1, 2024
  • Forward Dividend & Yield 0.32 (0.50%)
  • Ex-Dividend Date Feb 9, 2024
  • 1y Target Est 80.55

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

www.bio-techne.com

3,200

Full Time Employees

June 30

Fiscal Year Ends

Recent News: TECH

Performance Overview: TECH

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TECH
16.88%
S&P 500
6.92%

1-Year Return

TECH
18.27%
S&P 500
25.26%

3-Year Return

TECH
40.08%
S&P 500
22.00%

5-Year Return

TECH
36.93%
S&P 500
74.29%

Compare To: TECH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TECH

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    10.07B

  • Enterprise Value

    10.49B

  • Trailing P/E

    46.09

  • Forward P/E

    32.36

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.03

  • Price/Book (mrq)

    5.13

  • Enterprise Value/Revenue

    9.16

  • Enterprise Value/EBITDA

    27.90

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.58%

  • Return on Assets (ttm)

    6.32%

  • Return on Equity (ttm)

    11.83%

  • Revenue (ttm)

    1.14B

  • Net Income Avi to Common (ttm)

    224.11M

  • Diluted EPS (ttm)

    1.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    135.65M

  • Total Debt/Equity (mrq)

    28.30%

  • Levered Free Cash Flow (ttm)

    162.75M

Research Analysis: TECH

Company Insights: TECH

Research Reports: TECH

People Also Watch